Late-Stage Translation of Biomedical and Behavioral Research Results in Arthritis and Musculoskeletal and Skin Diseases from Academic/Non-profit Lab to Marketplace (SBIR [R43/R44] Clinical Trial Not Allowed)
Grant Opportunity Analysis
The National Institutes of Health (NIH) is offering a funding opportunity aimed at the late-stage translation of biomedical and behavioral research results related to arthritis and musculoskeletal diseases into the marketplace. This initiative, categorized under the Small Business Innovation Research (SBIR) grants (R43/R44), seeks to support small business concerns (SBCs) in collaboration with academic and non-profit labs to expedite the development and commercialization of diagnostic tools, therapies, and preventive measures, while specifically excluding clinical trials. The program emphasizes the importance of partnerships between technology developers and SBCs, requiring applicants to demonstrate their ability to advance projects with defined milestones and clear commercialization plans, with funding amounts up to $350,000 for Phase I and $2 million for Phase II grants. Interested applicants should note that the application deadline is September 5, 2025, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
Eligible Applicants
Other Eligible Applicants include the following:Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply.Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.Foreign components, as defined in the NIH Grants Policy Statement, may be allowed.